421 Kipling Street
About BridgeBio LLC
We focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. Our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting R&D with expert capabilities and placing them in a value maximizing corporate structure.
Hope through rigorous science.
122 articles with BridgeBio LLC
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB).
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its PRV for $110 million.
BridgeBio said it would sell the voucher for $110 million but did not disclose the identity of the company planning to acquire the voucher.
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today an exclusive license with Bristol Myers Squibb to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology.
BridgeBio announced it has signed an exclusive deal with Bristol-Myers Squibb to develop and commercialize a potential treatment for cancer.
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11th at 7:40 pm ET.
BridgeBio Pharma, Inc. today reported its financial results for the first quarter ended March 31, 2022 and provided an update on the Company’s operations.
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma, Inc. announced updated data from its ongoing Phase 2 open-label extension study of acoramidis in patients with symptomatic transthyretin amyloid cardiomyopathy.
Job cuts in biotech tend to occur during the end of a quarter, and the end of this first quarter is no different. Continue reading for news of four biotech companies making workforce layoffs this week.
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
BridgeBio Pharma, Inc. today announced positive data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i).
BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd., announced the execution of an asset purchase agreement for the sale of BridgeBio’s NULIBRY™ for Injection.
BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter ended December 31, 2021 and provided an update on the Company’s operations.
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
BridgeBio today announced that the first patient has been dosed in ADventure, its Phase 1/2 clinical trial of BBP-631.
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
12/28/2021BridgeBio Pharma reported topline data from Part A (Month 12) of its Phase III study of acoramidis for symptomatic transthyretin amyloid cardiomyopathy. The drug failed the study arm.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
BridgeBio Pharma, Inc. announced they have entered into a strategic collaboration to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors.